Login to Your Account

U.S. Patent Disclosures

Monday, August 15, 2011
• Allon Therapeutics Inc., of Vancouver, British Columbia, received a patent covering the method of use for lead product davunetide and its associated neuroprotective technology platform as a treatment for schizophrenia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription